548 related articles for article (PubMed ID: 34047459)
21. Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
Cheung JTK; Yang A; Wu H; Lau ESH; Shi M; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
Diabetes Res Clin Pract; 2023 Jan; 195():110203. PubMed ID: 36493912
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
Fujita KK; Ye F; Collister D; Klarenbach S; Campbell DJT; Chew DS; Quinn AE; Ronksley P; Lau D
Diabetes Obes Metab; 2024 Feb; 26(2):699-709. PubMed ID: 37997302
[TBL] [Abstract][Full Text] [Related]
25. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
26. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes.
Takeuchi M; Ogura M; Minoura T; Inagaki N; Kawakami K
Mayo Clin Proc; 2020 Feb; 95(2):265-273. PubMed ID: 32029085
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
[TBL] [Abstract][Full Text] [Related]
29. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
[TBL] [Abstract][Full Text] [Related]
30. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
31. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
[TBL] [Abstract][Full Text] [Related]
32. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
33. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
Liu T; Fan Z; Xiao B; He C; Wang S
Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
[TBL] [Abstract][Full Text] [Related]
34. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
35. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients.
Lim JH; Kwon S; Jeon Y; Kim YH; Kwon H; Kim YS; Lee H; Kim YL; Kim CD; Park SH; Lee JS; Yoo KD; Son HE; Jeong JC; Lee J; Lee JP; Cho JH
Transplantation; 2022 Sep; 106(9):e404-e412. PubMed ID: 35768908
[TBL] [Abstract][Full Text] [Related]
37. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
[TBL] [Abstract][Full Text] [Related]
38. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
39. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
[TBL] [Abstract][Full Text] [Related]
40. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS
Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]